Posted by Michael Wonder on 20 Jun 2020
ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence
19 June 2020 - Public input on drugs of concern will be accepted through 17 July 2020.
The Institute for Clinical and Economic Review (ICER) today posted a protocol describing our annual analysis — ICER’s “Unsupported Price Increase” (UPI) report — that will examine significant prescription drug price increases and determine whether or not new clinical evidence exists that could be used to support those increases.
Based on input from multiple stakeholders, ICER has made some revisions to the UPI assessment protocol that was released in 2019.
